Cardinal Health (CAH) Stock Forecast & Price Target

Cardinal Health is supported by a durable U.S. pharmaceutical distribution moat, with Cardinal, Cencora, and McKesson controlling over 90% of the market, while its scale, 99.8% on-time delivery, and 70,000-plus daily deliveries reinforce customer stickiness and pricing power. Its outlook is further strengthened by a shift toward higher-margin services, including Sonexus, MSO, biosimilars, and nuclear medicine, which are expected to expand the “Other” segment’s mix and drive higher operating income from about $3 billion of high-margin MSO revenue and growing theranostics exposure. Financially, fiscal 2025 revenue of $222.6 billion, adjusted EBIT of $2.8 billion, and $8.24 in adjusted EPS, plus a 2.5x gross-debt-to-adjusted-EBITDA ratio and robust free cash flow, give it flexibility to invest, repurchase shares, and compound earnings.

Cardinal Health is facing a fundamentally fragile earnings profile because its core Pharmaceutical and Specialty Distribution business still operates on razor-thin margins, with low-single-digit gross margins that are highly vulnerable to supply chain disruptions, input cost inflation, and weaker pricing power as competition and customer concentration intensify. While management is trying to offset these pressures with higher-margin services and growth segments, the company’s outlook is constrained by legislative uncertainty around drug pricing reform, slower expected top-line growth in core distribution, and the risk that biosimilars, GLP-1 mix, and alternate fulfillment models compress economics rather than expand them. Additional downside comes from execution and regulatory risk in nuclear operations, reliance on radioisotope supply and CDMO partnerships, and exposure to large customer relationships, including CVS at roughly 30% of fiscal 2025 sales, leaving earnings growth fragile even if adjusted gross margin improved to 3.7% in fiscal 2025.